Another ACT study of immune cells from TCR-tg mice found that CD4+ T cells were more efficient at tumor rejection than CD8+ T cells in vivo in 6 different tumor models and required MHC-II expression by host tissue, but not tumor, for clearance (26). The gene discussed is CD8A; the disease is neoplasm.